By Chris Wack
Hoth Therapeutics' shares surged more than 250% to $3 following positive interim results from its Phase 2a trial of HT-001, aimed at treating skin toxicities from EGFR inhibitors in cancer patients.
The stock hit its 52-week high of $3.08 earlier in the session, and is up more than 100% in the past 12 months.
The New York-based biopharmaceutical company said the trial showed 100% of participants met the primary efficacy endpoint, with significant skin improvement by six weeks. Additionally, 66% experienced reduced pain and itching, enhancing quality of life without needing to reduce EGFRi doses.
Hoth said this is a breakthrough as it avoids such dose reductions, which it says is a common solution to these skin issues.
The trial confirmed no adverse effects, highlighting HT-001's tolerability, said the company.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 07, 2025 10:40 ET (15:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.